Search Results

1 - 3 of 3 items

  • Keyword: sertraline x
Clear All Modify Search
Degradation of sertraline in water by suspended and supported TiO2


Pharmaceutical pollutants have been detected in many countries in surface and ground water after treatment in wastewater treatment plants. The presented studies concern the photocatalytic removal of one of SSRI antidepressants - sertraline from water using TiO2 photocatalyst. The process was conducted using two laboratory installations with periodic and flow reactors. Two forms of TiO2 was used in the photocatalytic reactions: suspended and supported onto a glass fabric. The studies shown that with increasing initial concentration of pharmaceutical, photoactivity decreases. For the initial concentration of 0.025 g/dm3, the best results – 94% removal – was achieved for the process conducted in the periodic reactor with TiO2 supported onto a glass fabric.

Open access
Antidepressant drugs for older patients on polypharmacy: a systematic review reveals best evidence for sertraline



There is almost no data on antidepressant prescribing in older adults treated with polypharmacy, although this population represents approximately 50% of older patients. These patients are frequently excluded from double-blind randomized controlled trials, meta-analyses and existing treatment guidelines. The main aim of this paper was to identify data on antidepressant prescribing in depressed older adults on polypharmacy using a systematic review.


Randomized controlled clinical trials (RCTs) and other clinical trials in Medline/PubMed without language limitation (-2017) were searched to identify those with older depressed patients on polypharmacy. Only elderly patients (>65 years as mean) were included. Only approved antidepressants were included.


The systematic search identified 26 different clinical trials, although only one clinical open label trial with sertraline met the final inclusion criteria. This sertraline trial indicated the absence of clinically important drug-drug interactions and confirmed the effectiveness and safety of sertraline in routine clinical practice. Heterogeneity in this trial was high in almost all the categories except attrition and reporting bias.


Sertraline has the highest evidence level in older adults with depression on polypharmacy. According to the results of this review and due to a low number of appropriate trials, a basic understanding of psychopharmacology is the possible approach to avoid serious problematic drug combinations in these patients. Newer RCTs are also urgently needed. This is the first systematic review including patients treated with polypharmacy, and therefore, its results are important in the field of evidence-based medicine.

Open access
Levels of pharmaceuticals in Slovene municipal and hospital wastewaters: a preliminary study


Pharmaceuticals in wastewater have clearly raised concern and a broad range of analytical methods has been used to assess the risk as accurately as possible. The aim of our study was to measure and compare the concentrations of atorvastatin, bisoprolol, carbamazepine, ciprofloxacin, clofibric acid, diclofenac, fluoxetine, metoprolol, and sertraline in wastewater samples taken from one municipal and one hospital wastewater treatment plant in Slovenia and to predict the potential environmental burden using the risk quotient. In both effluents only clofibric acid and fluoxetine were not detected. The measured concentrations of the remaining seven pharmaceuticals varied between the ng L−1 and the μg L−1 range. Hospital effluent showed higher concentrations, except for diclofenac and carbamazepine. However, high risk quotient was found only for ciprofloxacin and diclofenac in both municipal and hospital effluent. In conclusion, our method can provide a useful tool for systematic monitoring of pharmaceuticals commonly found in wastewater, which will enable a reliable assessment of the risks for the aquatic biota and humans. Knowing the risks will help to plan wastewater treatment and preserve our environment.

Open access